Rutgers, The State University of New Jersey

Manjeet Deshmukh

Patrick J Sinko

Simi Gunaseelan

Anupa R Menjoge

Yashveer Singh

Stanley Stein

Xiaoping Zhang

Matthew Sean Palombo

Jieming Gao

Marion K Gordon

Sherif Ibrahim

Siva N Priya Anumolu

Hilliard Kutscher

Formulations of cross-linkable polymers, capable of forming non-toxic and biocompatible hydrogels in situ, containing at least one of doxycycline or minocycline. Methods of using the hydrogels for treating the skin or ocular tissues of mammals exposed to vesicant compounds such as sulfur mustard (SM), nitrogen mustard (NM) or half mustard (2-chloroethyl ethyl sulfide (CEES)) are also disclosed.

Hydrogel formulation for dermal and ocular delivery

Novel classes of multi-arm polyalkylene oxide-based materials including PEG nanocarriers, nanogel particles, and aggregated nanogel particles are disclosed. These classes of compositions may be associated with therapeutic agents and targeting moieties, or visibility enhancing agents, and may have a modified surface structure. In some embodiments the PEG-based materials can be made to provide relatively high drug loads with improved solubility and targeted delivery.

Nanocarrier and nanogel compositions

This invention concerns an in situ biodegradable hydrogel drug delivery system in which the components are assembled in a manner that provides a mechanism for the timed cleavage of a particular amide bond in a covalently linked active agent or of the hydrogel structure.

Degradable hydrogel compositions and methods

Non-Small Cell Lung Carcinomas (NSCLCs) are treated with Gel Micro-Particles (GMPs) that passively accumulate in the lungs and contain Nano-Particles (NPs) combining one or more therapeutic agents that are cytotoxic to the NSCLC with one or more NSCLC active targeting ligands, as well as one or more other optional agents that increase cellular uptake, enhance the pro-apoptotic effect of the chemotherapeutic agent(s), and the like. NPs targeting other cancer cells are also disclosed, as well as NP-containing GMPs that reduce the occurrence of tumor metastasis.

Synergistic combinations to reduce particle dose for targeted treatment of cancer and its metastases

Growing community of inventors

Edison, NJ, United States of America

Manjeet Deshmukh